z-logo
open-access-imgOpen Access
Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection
Author(s) -
Anna Paula V. Moura,
Luiza C. B. Santos,
Carlos Ramon Nascimento Brito,
Edward Valencia,
Caroline Junqueira,
Adalberto Alves Pereira Filho,
Maurício Roberto Viana Sant’Anna,
Nelder F. Gontijo,
Daniella Castanheira Bartholomeu,
Ricardo Toshio Fujiwara,
Ricardo T. Gazzinelli,
Craig S. McKay,
Carlos Sanhueza,
M. G. Finn,
Alexandre F. Marques
Publication year - 2017
Publication title -
acs central science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.893
H-Index - 76
eISSN - 2374-7951
pISSN - 2374-7943
DOI - 10.1021/acscentsci.7b00311
Subject(s) - leishmania , visceral leishmaniasis , cutaneous leishmaniasis , virology , epitope , biology , vaccination , leishmaniasis , immune system , leishmania infantum , spleen , leishmania mexicana , parasite load , virus like particle , microbiology and biotechnology , antibody , immunology , parasite hosting , biochemistry , world wide web , gene , computer science , recombinant dna
Secreted and surface-displayed carbohydrates are essential for virulence and viability of many parasites, including for immune system evasion. We have identified the α-Gal trisaccharide epitope on the surface of the protozoan parasites Leishmania infantum and Leishmania amazonensis , the etiological agents of visceral and cutaneous leishmaniasis, respectively, with the latter bearing larger amounts of α-Gal than the former. A polyvalent α-Gal conjugate on the immunogenic Qβ virus-like particle was tested as a vaccine against Leishmania infection in a C57BL/6 α-galactosyltransferase knockout mouse model, which mimics human hosts in producing high titers of anti-α-Gal antibodies. As expected, α-Gal-T knockout mice infected with promastigotes of both Leishmania species showed significantly lower parasite load in the liver and slightly decreased levels in the spleen, compared with wild-type mice. Vaccination with Qβ-α-Gal nanoparticles protected the knockout mice against Leishmania challenge, eliminating the infection and proliferation of parasites in the liver and spleen as probed by qPCR. The α-Gal epitope may therefore be considered as a vaccine candidate to block human cutaneous and visceral leishmaniasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom